David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Business Ethics Education 2 (1):97-121 (2005)
The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Access to Essential Medicines (B). Journal of Business Ethics Education 2 (1):123-132.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine & Ethics 40 (2):234-250.
Joo-Young Lee & Paul Hunt (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. Journal of Law, Medicine & Ethics 40 (2):220-233.
Richard E. Ashcroft (2005). Access to Essential Medicines: A Hobbesian Social Contract Approach. Developing World Bioethics 5 (2):121–141.
Debora Diniz (2009). Rationing the Access to High Cost Medicines in Developing Countries. Developing World Bioethics 9 (2).
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
Klaus M. Leisinger (2009). Corporate Responsibilities for Access to Medicines. Journal of Business Ethics 85 (1):3 - 23.
Matthew Rimmer (2008). Race Against Time: The Export of Essential Medicines to Rwanda. Public Health Ethics 1 (2):89-103.
Harvey E. Bale (2005). Industry, Innovation and Social Values. Science and Engineering Ethics 11 (1):31-40.
Robert C. Bird (2009). Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects. Journal of Law, Medicine & Ethics 37 (2):209-221.
Rudolf V. van Puymbroeck (2010). Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: Conversion + Calculation. Journal of Law, Medicine & Ethics 38 (3):520-549.
Frank R. Lichtenberg (2005). Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries. Journal of Medicine and Philosophy 30 (6):663 – 690.
Onyeka K. Osuji & Okechukwu Timothy Umahi (2012). Pharmaceutical Companies and Access to Medicines – Social Integration and Ethical CSR Resolution of a Global Public Choice Problem. Journal of Global Ethics 8 (2-3):139-167.
Added to index2012-03-18
Total downloads18 ( #141,475 of 1,699,674 )
Recent downloads (6 months)12 ( #53,539 of 1,699,674 )
How can I increase my downloads?